Palisade Bio Inc (PALI)

Apr 13, 2025

FY2025 EPS Estimates for Palisade Bio Increased by Analyst - American Banking and Market News

Apr 13, 2025

Apr 12, 2025

FY2025 EPS Forecast for Palisade Bio Raised by Analyst - Defense World

Apr 12, 2025

Apr 11, 2025

Analysts Issue Forecasts for Palisade Bio Q1 Earnings - Defense World

Apr 11, 2025

Apr 09, 2025

Palisade Bio reports safe PALI-2108 trials, eyes H1 2025 data - Investing.com Canada

Apr 09, 2025

Apr 09, 2025

Palisade Bio reports safe PALI-2108 trials, eyes H1 2025 data By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 09, 2025

Palisade Bio Completes Dosing In Phase 1A Portion Of Ongoing Phase 1A/B Study Of Pali-2108 - MarketScreener

Apr 09, 2025

Apr 09, 2025

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire

Apr 09, 2025

Apr 09, 2025

Clinical Trial Success: Palisade Bio's UC Treatment Achieves Key Safety Milestone - Stock Titan

Apr 09, 2025

Mar 31, 2025

PALI stock plunges to 52-week low, touches $0.64 amid market challenges - Investing.com Australia

Mar 31, 2025

Mar 25, 2025

Palisade Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 25, 2025

Mar 24, 2025

Palisade Bio Inc. (PALI) reports earnings - qz.com

Mar 24, 2025

Mar 21, 2025

PALI stock plunges to 52-week low, hitting $0.74 By Investing.com - Investing.com South Africa

Mar 21, 2025

Mar 21, 2025

PALI stock plunges to 52-week low, hitting $0.74 - Investing.com

Mar 21, 2025

Mar 21, 2025

Palisade Bio Inc expected to post a loss of $1.99 a shareEarnings Preview - TradingView

Mar 21, 2025

Mar 18, 2025

Palisade Bio (PALI) Expected to Announce Earnings on Tuesday - Defense World

Mar 18, 2025

Mar 17, 2025

Palisade Bio begins dosing subjects in last cohort of ulcerative colitis drug trial - Yahoo

Mar 17, 2025

Mar 14, 2025

Palisade Bio Begins Dosing Ulcerative Colitis Patients in PALI-2108 Trial -March 14, 2025 at 08:58 am EDT - Marketscreener.com

Mar 14, 2025

Mar 14, 2025

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108 - GlobeNewswire

Mar 14, 2025

Mar 14, 2025

Palisade Bio Reports Encouraging Preliminary Safety and Tolerability Data for PALI-2108 in Phase 1a/b Study for Ulcerative Colitis - Nasdaq

Mar 14, 2025

Mar 14, 2025

Palisade Bio's UC Treatment Advances: Zero Serious Events as Patient Trial Launches - StockTitan

Mar 14, 2025

Mar 12, 2025

Palisade Bio to present ulcerative colitis treatment data By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Palisade Bio Announces Two Abstracts Selected to be - GlobeNewswire

Mar 12, 2025

Mar 12, 2025

Palisade Bio to present ulcerative colitis treatment data - Investing.com

Mar 12, 2025

Mar 12, 2025

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025 - GlobeNewswire

Mar 12, 2025

Mar 07, 2025

Palisade Bio (PALI) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Mar 07, 2025

Mar 04, 2025

Palisade Bio Participates in Virtual Investor 'What This Means” Segment - The Manila Times

Mar 04, 2025

Mar 04, 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Mar 04, 2025

Mar 04, 2025

Can Palisade Bio's Promising UC Drug Candidate Transform Treatment Options? - StockTitan

Mar 04, 2025

Mar 01, 2025

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 01, 2025

Feb 20, 2025

Palisade Bio secures Canadian tax credit for drug study By Investing.com - Investing.com Nigeria

Feb 20, 2025

Feb 20, 2025

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada's SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC) - The Manila Times

Feb 20, 2025

Feb 20, 2025

Palisade Bio secures Canadian tax credit for drug study - Investing.com India

Feb 20, 2025

Feb 20, 2025

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from - GlobeNewswire

Feb 20, 2025

Feb 20, 2025

Canadian Government Backs This Promising Ulcerative Colitis TreatmentWhat's Behind the $1.39M Investment? - StockTitan

Feb 20, 2025

Feb 20, 2025

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire

Feb 20, 2025

Feb 19, 2025

Autonomix Medical, Inc. Participates in the Virtual Investor 'Top 5 for '25” On-Demand Conference - The Manila Times

Feb 19, 2025

Feb 19, 2025

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand - Big News Network

Feb 19, 2025

Feb 19, 2025

Inside Palisade Bio's Ambitious 2025 Roadmap: 5 Critical Growth Drivers Revealed - StockTitan

Feb 19, 2025

Feb 17, 2025

PALI stock plunges to 52-week low, touches $1.34 - MSN

Feb 17, 2025

Feb 14, 2025

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update - BioSpace

Feb 14, 2025

Feb 11, 2025

PALI-2108 colon-activated prodrug prevents ulcerative colitis progression - BioWorld Online

Feb 11, 2025

Feb 10, 2025

PALI’s Q2 earnings predictions: What the experts say - US Post News

Feb 10, 2025

Feb 10, 2025

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis - GlobeNewswire

Feb 10, 2025

Feb 10, 2025

Q4 Earnings Roundup: Children's Place (NASDAQ:PLCE) And The Rest Of The Apparel Retailer Segment - The Globe and Mail

Feb 10, 2025

Feb 10, 2025

Palisade Bio's UC Drug Outperforms Standard Treatments in Preclinical StudiesKey Data Unveiled - StockTitan

Feb 10, 2025

Feb 07, 2025

Pre-market Movers: PALI, KROS, AVGR, TRVI... - RTTNews

Feb 07, 2025

Feb 06, 2025

Reviewing Protara Therapeutics (NASDAQ:TARA) and Palisade Bio (NASDAQ:PALI) - Defense World

Feb 06, 2025

Feb 05, 2025

JPMorgan Chase & Co. Purchases Shares of 8,200 Palisade Bio, Inc. (NASDAQ:PALI) - Defense World

Feb 05, 2025